Biotech | March 03, 2022
Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
